



Statement on Climate Change

CSL is committed to a healthier world.

Our vision is a sustainable future for all our stakeholders, our employees, communities, patients and donors, inspired by innovative science and a values-driven culture.

Our commitment to a healthier world means delivering for both people and our planet.

Climate change poses a risk for the health of the global population, businesses, communities and the economy. A warming planet increases the risk of wildfires, rising sea levels, extreme heat, severe weather and droughts. These hazards can both have a direct effect on population health and further stress health care infrastructure, including the network of global manufacturing facilities and warehouses utilised by CSL in the production of life-saving medicines and therapies.

CSL recognises that responsible management and efficient use of natural resources is key to the company's sustainable growth and its ability to deliver efficient and reliable supply of life-saving medicines. We support the Paris Agreement and global efforts to limit global warming to 1.5 degrees Celsius, to reduce even worse impacts in the long-term, as reiterated in the most recent Assessment Report by the Intergovernmental Panel on Climate Change (IPCC).

Our commitment

In recognition of the role that we can play in contributing to global efforts to address climate change and support the transition to a low carbon future, CSL has made a commitment to minimise our climate change impact by reducing our greenhouse gas (GHG) emissions.

For a century we have strived to provide our life-saving medicines in an efficient, inclusive and environmentally respectful way. We take this responsibility seriously, and our promise is to continue to further build environmental considerations into our business so we can deliver a sustainable world for the next century and beyond.

In 2025, the Science Based Targets initiative (SBTi) approved CSL's near-term science based emissions reduction targets. These are:

- CSL commits to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY 2030 (from a FY2021 base year);¹
- CSL commits that 73.1% of CSL's suppliers by emissions – Scope 3 categories: purchased goods and services, capital goods, upstream transportation and distribution, business travel, and downstream transportation and distribution – have science-based targets by FY2030.

Our SBTi-approved targets help align CSL to the goal of limiting global warming to 1.5 degrees Celsius. Importantly, the timeframes also align to CSL's 2030 business strategy, ensuring the targets are incorporated into our detailed operational plans.

Our decarbonisation roadmap to achieve our emissions reductions targets will occur through:

- increased energy efficiency;
- a push toward more renewable power;
- switching fuels to less carbon intensive energy sources;
- re-designing some of our manufacturing sites;
- utilising best-in-class facility design for greenfield sites and new buildings;
- revised procurement standards and award criteria;
- supplier enablement through advocacy and education; and
- strategic partnerships to innovate and collaborate with our suppliers.

Our targets ensure we can contribute to limiting global warming, while continuing to save and improve the lives of our patients and protect public health.

In addition to climate resilience, energy and emissions reductions are key components in CSL's Corporate Sustainability Strategy. Our continued commitment to proactively mitigate and adapt to climate change is also demonstrated through the following organisational initiatives.

Identifying and managing Climate Change risks and opportunities

CSL has a practice of periodically undertaking detailed enterprise-wide climate change risk and opportunity assessments using the most recent IPCC Assessment Reports. This includes physical and transition climate scenario analysis to better understand the ways in which future climate change risks and opportunities may impact the business and what controls could be implemented to mitigate these, across our plasma centres, critical suppliers, manufacturing facilities and warehouses. Consideration of potential climate change risks and opportunities is an integrated part of CSL's business management framework. It is included in strategic planning through to monitoring and reporting, such as in assessing new capital investment opportunities, particularly where energy and water security are critical; in staff performance management where there are relevant responsibilities; and in disclosure through the annual reporting process.

CSL maintains a watching brief on scientific research on how climate change may affect human health, particularly the possibility of increased incidence of infectious diseases. This may provide opportunities for CSL with increased demand for new or existing products and to leverage our core capabilities as a leading biopharmaceutical company with an established research and development program, and potentially take an increased role in humanitarian efforts to combat any spread of disease.

Participating in government climate change programs

CSL supports the use of appropriate market mechanisms to address climate change where they are consistent with international approaches, and are designed to encourage investment and innovation in GHG emission mitigating technologies, while limiting adverse impacts on national economies.

Our policy is to meet all applicable statutory environmental regulations and extends to regulations concerning energy consumption and GHG emissions. We also assess any risks or opportunities that may arise from changing policies and climate change market mechanisms, such as international carbon prices used to manage GHG emissions. Where our skills and expertise are relevant, we will openly work with government, non-government organisations and industry groups to share best practice, and similarly seek to better understand how other organisations and industries adopt adaptation and mitigation strategies to support global climate change goals.

1. In 2022, CSL announced its initial target to reduce emissions associated with its own operations by 40%. This target has since been updated to 42% to align with the SBTi's reporting period for calendar years. CSL's Scope 3-related target, approved by the SBTi (as outlined above), is part of CSL's broader intention to engage suppliers who account for 67% of all CSL's total Scope 3 emissions. CSL aims for these suppliers to have Scope 1 and 2 emissions reduction targets aligned* with the SBTi. This broader intention applies to suppliers across all Scope 3 categories.

The target boundary includes land-related emissions and removals from bioenergy feedstocks.

* Either the supplier has SBTi-validated targets, or CSL has conducted due diligence to confirm that the supplier's targets meet SBTi criteria.